China Evergrande New Energy Vehicle Group Limited (HKG:0708)
0.1700
+0.0020 (1.19%)
Mar 31, 2025, 4:08 PM HKT
HKG:0708 Revenue
China Evergrande New Energy Vehicle Group had revenue of 38.38M CNY in the half year ending June 30, 2024, with 59.20% growth. This brings the company's revenue in the last twelve months to 1.22B, up 514.37% year-over-year. In the year 2023, China Evergrande New Energy Vehicle Group had annual revenue of 1.34B with 900.03% growth.
Revenue (ttm)
1.22B CNY
Revenue Growth
+514.37%
P/S Ratio
1.40
Revenue / Employee
912.06K CNY
Employees
1,342
Market Cap
1.84B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.34B | 1.21B | 900.03% |
Dec 31, 2022 | 134.01M | -2.40B | -94.71% |
Dec 31, 2021 | 2.53B | -12.96B | -83.66% |
Dec 31, 2020 | 15.49B | 9.85B | 174.80% |
Dec 31, 2019 | 5.64B | 2.50B | 79.88% |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
JD Health International | 71.34B |
BeOne Medicines AG | 35.81B |
Sino Biopharmaceutical | 33.49B |
Alibaba Health Information Technology | 32.81B |
CSPC Pharmaceutical Group | 28.49B |
WuXi Biologics | 21.98B |
Hansoh Pharmaceutical Group Company | 14.45B |
Innovent Biologics | 12.52B |